Company news

Ionis Pharmaceuticals, Inc. news in 2025

Ionis Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)

December 1, 2025

Ionis receives U.S. FDA Breakthrough Therapy designation for olezarsen for severe hypertriglyceridemia (sHTG)

November 30, 2025

DAWNZERA™ (donidalorsen) receives positive opinion from CHMP, recommended for approval in EU for hereditary angioedema (HAE)

November 13, 2025

Ionis Prices Convertible Notes Offering to Refinance 2026 Convertible Notes

November 12, 2025

Ionis to present at upcoming investor conferences

November 11, 2025

Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes

November 10, 2025

Groundbreaking pivotal study results of olezarsen for severe hypertriglyceridemia (sHTG) presented as a late breaker at AHA Scientific Sessions

November 8, 2025

Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting

November 5, 2025

Ionis reports third quarter 2025 financial results and highlights progress on key programs

October 28, 2025

Detailed data from the landmark CORE and CORE2 pivotal studies of olezarsen for sHTG to be presented as a late breaker at AHA Scientific Sessions

October 26, 2025

Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture

October 22, 2025

Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society

October 20, 2025

Ionis to hold third quarter 2025 financial results webcast

October 15, 2025

Ionis showcases transformational medicines and industry-leading pipeline at Innovation Day

October 6, 2025

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

September 21, 2025

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

September 18, 2025

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

September 11, 2025

Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals

September 11, 2025

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

September 8, 2025

Ionis to host investors and analysts for Innovation Day 2025

September 7, 2025

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

September 1, 2025

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

August 20, 2025

Ionis reports second quarter 2025 financial results and highlights progress on key programs

July 29, 2025

TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)

July 24, 2025

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice

July 20, 2025

Ionis to hold second quarter 2025 financial results webcast

July 15, 2025

Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results

June 24, 2025

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

June 11, 2025

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

June 10, 2025

Ionis announces positive topline results from Essence study of olezarsen in people with moderately elevated triglycerides

May 18, 2025

Ionis to host 2025 virtual Annual Meeting of Stockholders

May 5, 2025

Ionis reports first quarter 2025 financial results

April 29, 2025

New Harris Poll findings reveal HAE patients are unsatisfied with current prophylactic treatment options, with over 90% interested in trying new therapies

April 29, 2025

Ionis to hold first quarter 2025 financial results webcast

April 15, 2025

Ionis to host expert panel discussion on sHTG

April 2, 2025

Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S.

March 25, 2025

Ionis and Ono announce global license agreement for sapablursen in polycythemia vera

March 10, 2025

WAINZUA (eplontersen) approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

March 9, 2025

New positive donidalorsen data to be presented at AAAAI/WAO Joint Congress highlight sustained HAE attack rate reduction and disease control

February 19, 2025

Ionis reports fourth quarter and full year 2024 financial results

February 18, 2025

Ionis to hold fourth quarter and full year 2024 financial results webcast

February 4, 2025

Ionis enters new chapter in 2025 as commercial-stage biotech with multiple independent product launches anticipated and continued late-stage pipeline momentum

January 12, 2025

Ionis to present at 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

Calls in 2025

Decks in 2025